Fulcrum Therapeutics share price today

Fulcrum Therapeutics, Inc.'s share price was $3.77 at the close on 4 November 2026. That is 34.5% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $13, and at that close it sat 3% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running.

Over the last 1 year the share price moved −52% while the S&P 500 moved +23%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Fulcrum Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Fulcrum Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Fulcrum Therapeutics, Inc. earned $55.4 M of net profit in the Jun 2024 quarter. The full FY24 year was a loss of $9.7 M. That is 69.3% of the quarter's revenue. The same quarter a year earlier lost $24.8 M. 11 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Fulcrum Therapeutics, Inc. reported $80.0 M of revenue in the Jun 2024 quarter, +8,990.9% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 3 years it has grown 61.0% a year on average. The last full year, FY24, came in at $80.0 M.

Revenue is everything the company billed its customers in the period.

FY24 revenue was $80.0 M, +2,752.0% on the year before.

Recent pace: the last four quarters grew +2,232.3% on average, against 61.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +1,939.8%, against +120.5% a year over the last 8 quarters (accelerating).

Fulcrum Therapeutics, Inc.'s operating margin was 65.6% in the Jun 2024 quarter, 3,167.0 percentage points higher than the same quarter a year ago. Over the last four quarters it has moved +9,536.8 percentage points. Across 4 years it has been between −3,945.2% and −24.8%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +9,536.8 percentage points on the year while gross margin changed +5,644.5 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Fulcrum Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY24 its operations used $2.2 M of cash, against −$9.7 M of profit. After $278 K of spending on assets, free cash was −$2.5 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Fulcrum Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.7 M on assets over the last 3 years. Averaged over those years that is 1.1% of FY24 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $2.7 M over the last 3 years.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

Fulcrum Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Fulcrum Therapeutics, Inc. at 3.6× its FY24 revenue of $80.0 M. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Fulcrum Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Fulcrum Therapeutics, Inc. earned a ROE of −4% in FY24. That is up from a low of −55% in FY22. Its return on capital used (ROIC) is 39.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a −12.2% net margin and 0.31× asset turnover (sales divided by assets).

Why the return is what it is (FY24): a −12.2% net margin × 0.31× asset turnover × 1.07× leverage (assets divided by equity) ≈ −4.0% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: −20.1% − 19.1% = −39.2 percentage points. The 19.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Fulcrum Therapeutics, Inc. has total debt of $5.3 M against shareholder equity of $311 M as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.07 in FY22 to 0.02 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

10.6% of Fulcrum Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 4.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Fulcrum Therapeutics, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

There is no score against its industry: Fulcrum Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Fulcrum Therapeutics is the 176th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: vTv Therapeutics Inc., Ocugen, Inc. and SAB Biotherapeutics, Inc. Just below it: Inhibikase Therapeutics, Inc., Q32 Bio Inc. and Bicycle Therapeutics plc.

Biotechnology companies close in size

173. vTv Therapeutics Inc. $299 million
174. Ocugen, Inc. $297 million
175. SAB Biotherapeutics, Inc. $289 million
176. Fulcrum Therapeutics, Inc. $288 million
177. Inhibikase Therapeutics, Inc. $285 million
178. Q32 Bio Inc. $267 million
179. Bicycle Therapeutics plc $261 million

All 211 Biotechnology companies, largest first

Companies close in size in other industries

3175. Dave & Buster's Entertainment, Inc. $286 million · Entertainment
3176. CPI Card Group Inc. $286 million · Credit Services
3177. Fulcrum Therapeutics, Inc. $285 million
3178. First Northern Community Bancorp $285 million · Banks - Regional
3179. Gevo, Inc. $285 million · Specialty Chemicals

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.